J, the $6.4B question is would that be too much trouble and not enough profit potential even for a BP. From the benefit of the society standpoint, it makes sense. However, from a business standpoint, does downgrading the #1 killer (CVD) in the world to #3 killer in the world make business sense in the long run, especially since the generics would reap the benefits in less than 8 years?
News 
Market Data 
Discover 
